Lupin has received approval for cinacalcet tablets and phenylephrine and ketorolac intraocular solution, which had a market value of roughly $1.5 billion and $42.8 million, respectively.
Drug Store News is shedding some light on the luminaries of the generics industry who are committed to making cost savings possible, while simultaneously helping to keep patients healthy.